Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2019

View Archived Issues

PARP degradation joins trapping, inhibition

Tau spreads quickly but kills slowly

HLX-11 receives IND application acceptance notification from NMPA

Cartesian initiates phase I/II study of its lead CAR-T candidate, Descartes-08

eFFECTOR Therapeutics initiates early clinical study of zotatifin in advanced solid tumors

Further interim data presented from phase Ib study of EDP-1815 in patients with psoriasis

Initiation of phase Ib study of mavorixafor in severe congenital neutropenia

Regeneron provides updates on phase III development program of Libtayo in NSCLC

Daiichi Sankyo presents in vitro and in vivo data for DS-1039

NXP-031 leads to significant improvement of motor deficit in MPTP-induced mouse model of PD

Investigators design mouse model of dwarfism with PCSK1 mutation

EOLO-42016 shows promise in model of inherited ALS

Enzyme-replacement gene therapy encoding glucocerebrosidase attenuates PD phenotype

First phase I data presented for influenza vaccine OVX-836

Small molecules clear mutant Huntingtin protein

Tempest Therapeutics patents prostanoid EP2 and EP4 receptor antagonists

Incyte patent describes MAP4K1 inhibitors

TNBG-5602 induces lipid accumulation and antiproliferation in liver cancer cells through PPARgamma

Ark Biosciences reports topline proof-of-concept data for ziresovir in RSV

HitGen identifies new NTRK1 inhibitors

ATM and DNA-PK kinase inhibitors revealed in XRad Therapeutics patent

Shenzhen Targetrx Biotechnology patent details new tyrosine kinase inhibitors

4D reports preliminary phase I/II data on MRx-0518 with pembrolizumab in advanced malignancies

Dystrogen reports cardioprotective effects of DEC cells in Duchenne muscular dystrophy

BerGenBio reports updated phase II data on bemcentinib in advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...